Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

793
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
793
Asthma-I: Introduction01:29

Asthma-I: Introduction

2.8K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.8K
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

539
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
539
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

2.7K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.7K
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

561
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
561
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

3.2K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sustained asthma control and remission in real-world patients with severe eosinophilic asthma receiving benralizumab: XALOC-2.

The Journal of asthma : official journal of the Association for the Care of Asthma·2026
Same author

Prioritising efficacy over convenience.

American journal of respiratory and critical care medicine·2026
Same author

Benralizumab: Bringing winds of change to eosinophil-associated diseases.

The World Allergy Organization journal·2025
Same author

Early and Sustained Asthma Control and Remission in Real-World Patients With Severe Eosinophilic Asthma Treated With Benralizumab: XALOC-2.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2025
Same author

[Efficacy and clinical remission in patients with severe asthma and blood eosinophil counts ≥150 cells/μl treated with benralizumab: a sub-analysis of the Phase 3 MIRACLE study].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases·2025
Same author

Severe asthma is characterized by a sex-specific ILC landscape and aberrant airway profile that is suppressed by anti-IL-5/5Rα biologics.

Science translational medicine·2025

Related Experiment Video

Updated: Oct 1, 2025

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography
08:58

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography

Published on: July 10, 2018

43.3K

FeNO in Asthma.

Lola Loewenthal1,2, Andrew Menzies-Gow1

  • 1Department of Respiratory Medicine, Royal Brompton and Harefield Hospitals, London, United Kingdom.

Seminars in Respiratory and Critical Care Medicine
|March 7, 2022
PubMed
Summary

Fractional exhaled nitric oxide (FeNO) testing offers an objective measure for airway inflammation in asthma diagnosis and management. This noninvasive test aids in predicting treatment response and monitoring adherence, improving overall asthma care.

More Related Videos

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.0K
Murine Model of Allergen Induced Asthma
08:05

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

40.6K

Related Experiment Videos

Last Updated: Oct 1, 2025

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography
08:58

Assessment of Respiratory Function in Conscious Mice by Double-chamber Plethysmography

Published on: July 10, 2018

43.3K
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.0K
Murine Model of Allergen Induced Asthma
08:05

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

40.6K

Area of Science:

  • Pulmonary Medicine
  • Allergy and Immunology
  • Biomarker Research

Background:

  • Asthma affects 350 million globally, characterized by airway inflammation and hyperreactivity.
  • Traditional diagnosis relies on symptoms, risking misdiagnosis and suboptimal treatment.
  • Fractional exhaled nitric oxide (FeNO) is an exhaled biomarker indicating airway inflammation, particularly in type 2 asthma.

Purpose of the Study:

  • To evaluate the role of FeNO testing in improving asthma diagnosis and management.
  • To explore FeNO's utility in predicting treatment response and monitoring disease progression.
  • To assess the cost-effectiveness and clinical integration of FeNO testing.

Main Methods:

  • FeNO testing as a noninvasive, accessible method to measure airway inflammation.
  • Comparison of FeNO levels with clinical symptoms, eosinophil counts, and treatment responses.
  • Analysis of established FeNO cut-off values from major respiratory guidelines (ATS, GINA, NICE).

Main Results:

  • FeNO testing enhances asthma diagnostic accuracy when combined with clinical assessment.
  • Elevated FeNO levels predict response to inhaled corticosteroids (ICS) and can monitor ICS adherence.
  • FeNO levels correlate with asthma exacerbation risk and lung function decline, and show potential in predicting biologic therapy response.

Conclusions:

  • FeNO testing is a valuable, objective tool for asthma diagnosis and management.
  • Integrating FeNO into clinical practice improves diagnostic accuracy and treatment personalization.
  • FeNO monitoring offers a cost-effective strategy for optimizing asthma care and predicting outcomes.